Cerus (CERS) Cut to Sell at BidaskClub
BidaskClub downgraded shares of Cerus (NASDAQ:CERS) from a hold rating to a sell rating in a research report report published on Tuesday.
Several other equities analysts have also recently weighed in on CERS. ValuEngine cut shares of Cerus from a sell rating to a strong sell rating in a research note on Friday, September 1st. Zacks Investment Research downgraded Cerus from a hold rating to a sell rating in a report on Tuesday, October 3rd. Cowen set a $6.00 price target on Cerus and gave the company a buy rating in a report on Thursday, October 5th. Robert W. Baird reaffirmed a buy rating and set a $5.00 price target on shares of Cerus in a report on Friday, December 1st. Finally, BTIG Research reaffirmed a neutral rating on shares of Cerus in a report on Friday, December 8th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The stock has an average rating of Hold and a consensus price target of $6.17.
Cerus (NASDAQ CERS) traded down $0.09 during trading hours on Tuesday, hitting $3.71. 440,900 shares of the company traded hands, compared to its average volume of 966,076. Cerus has a twelve month low of $1.93 and a twelve month high of $5.16. The company has a debt-to-equity ratio of 0.80, a current ratio of 3.71 and a quick ratio of 3.11.
Cerus (NASDAQ:CERS) last released its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.03. Cerus had a negative net margin of 159.35% and a negative return on equity of 142.18%. The business had revenue of $10.80 million during the quarter, compared to analysts’ expectations of $11.95 million. During the same period last year, the business earned ($0.14) earnings per share. The firm’s revenue was up 5.9% on a year-over-year basis. sell-side analysts anticipate that Cerus will post -0.59 EPS for the current year.
A number of institutional investors have recently made changes to their positions in the business. Elk Creek Partners LLC lifted its holdings in shares of Cerus by 6.8% during the third quarter. Elk Creek Partners LLC now owns 6,128,026 shares of the biotechnology company’s stock worth $16,730,000 after buying an additional 388,741 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Cerus by 3.9% during the second quarter. Vanguard Group Inc. now owns 4,892,503 shares of the biotechnology company’s stock worth $12,281,000 after buying an additional 184,076 shares in the last quarter. Senvest Management LLC lifted its holdings in shares of Cerus by 0.7% during the third quarter. Senvest Management LLC now owns 2,960,398 shares of the biotechnology company’s stock worth $8,082,000 after buying an additional 20,000 shares in the last quarter. Ark Investment Management LLC lifted its holdings in shares of Cerus by 126.5% during the second quarter. Ark Investment Management LLC now owns 1,680,925 shares of the biotechnology company’s stock worth $4,219,000 after buying an additional 938,647 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in shares of Cerus by 3.2% during the second quarter. Northern Trust Corp now owns 1,269,773 shares of the biotechnology company’s stock worth $3,186,000 after buying an additional 39,684 shares in the last quarter. 58.46% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Cerus (CERS) Cut to Sell at BidaskClub” was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://theolympiareport.com/2017/12/15/cerus-cers-cut-to-sell-at-bidaskclub.html.
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with Analyst Ratings Network's FREE daily email newsletter.